Halozyme declines after Q4 bottom line miss, reiterates 2026 guidance
Source: SeekingAlpha
2026-02-18 14:48:06 ET
More on Halozyme Therapeutics
- Halozyme Delivers Record FY2025 As 2026 Sets Up A Major Profitability Surge
- Halozyme Therapeutics, Inc. 2025 Q4 - Results - Earnings Call Presentation
- Halozyme Therapeutics, Inc. (HALO) Q4 2025 Earnings Call Transcript
- Halozyme outlines $1.71B–$1.81B 2026 revenue target as new subcutaneous technologies expand pipeline
- Halozyme Therapeutics Non-GAAP EPS of -$0.24 misses by $2.44, revenue of $451M beats by $4.86M
Read the full article on Seeking Alpha
For further details see:
Halozyme declines after Q4 bottom line miss, reiterates 2026 guidance
Halozyme Therapeutics Inc.
NASDAQ: HALO
HALO Trading
-1.32% G/L:
$66.815 Last:
431,756 Volume:
$67.31 Open:
HALO Latest News
March 06, 2026 08:00:00 am
U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma
February 17, 2026 04:01:00 pm
HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE
HALO Stock Data
$9,572,395,800
114,186,687
0.24%
276
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
